Plus Therapeutics, Inc. reported its financial results for the first quarter of 2026, revealing a net loss of $6.9 million, a significant improvement compared to a net loss of $17.4 million in the same period of 2025. The company recognized grant revenue of $1.0 million, slightly down from $1.1 million year-over-year. Total operating expenses surged to $8.1 million, up from $4.6 million, primarily driven by increased research and development costs, which rose to $2.9 million from $1.8 million, and general and administrative expenses, which increased to $5.3 million from $2.8 million.
The company’s cash and cash equivalents decreased to $3.0 million as of March 31, 2026, down from $4.3 million at the end of 2025. However, total current assets increased to $18.0 million from $15.2 million, while current liabilities decreased significantly to $8.0 million from $12.3 million, resulting in a working capital improvement to $10.1 million. This positive shift in working capital reflects the company's ongoing efforts to manage its financial position amid rising operational costs.
Strategically, Plus Therapeutics has made notable advancements, including the reintroduction of its CNSide Test, which is now being utilized in clinical trials and has secured agreements with major payers such as United Healthcare and Humana. The company also completed a public offering in January 2026, raising approximately $13.9 million in net proceeds, which is expected to support its clinical development programs and operational needs. Additionally, the company implemented a 1-for-25 reverse stock split effective April 2, 2026, aimed at regaining compliance with Nasdaq listing requirements.
Looking ahead, Plus Therapeutics anticipates increased research and development expenditures as it progresses with its clinical trials, particularly for its lead candidate, rhenium (186Re) obisbemeda, which is under investigation for treating central nervous system cancers. The company is also focused on expanding its CNSide diagnostics platform and expects to see growth in diagnostic revenue as it continues to establish its market presence. However, the company acknowledges the need for additional capital to sustain its operations and fund future clinical development, raising concerns about its ability to continue as a going concern if sufficient funding is not secured.
About PLUS THERAPEUTICS, INC.
Plus Therapeutics, Inc. develops targeted radiotherapeutics and medical devices for central nervous system and solid organ cancers. Its core platform delivers high-dose radiation directly to tumors, aiming to improve safety and efficacy over traditional therapies. The company’s key products include REYOBIQ and CNSide diagnostics, targeting brain, leptomeningeal, and pediatric cancers, with a focus on innovative, minimally invasive treatments and companion diagnostic tools.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.